Related Experiment Videos
Rationale for thromboprophylaxis in lower joint arthroplasty
1Shiley Center for Orthopaedic Research and Education, Scripps Clinic, La Jolla, California, USA.
American Journal of Orthopedics (Belle Mead, N.J.)
|December 6, 2007
Summary
Prophylaxis significantly reduces deep vein thrombosis (DVT) and pulmonary embolism (PE) after major orthopedic surgery. Evidence shows minimal bleeding risk, making VTE prophylaxis a top safety practice for at-risk patients.
Area of Science:
- Orthopedics
- Cardiovascular Medicine
- Pharmacology
Background:
- Deep vein thrombosis (DVT) rates after major orthopedic surgery can be as high as 40-60% without preventive measures.
- Venous thromboembolism (VTE) prophylaxis is a critical safety practice for hospitalized patients, particularly after orthopedic procedures.
- Guidelines for VTE prophylaxis in total knee arthroplasty (TKA), total hip arthroplasty (THA), and hip fracture surgery have been established since 1986.
Purpose of the Study:
- To review the evidence supporting primary thromboprophylaxis in orthopedic surgery.
- To highlight the importance of VTE prophylaxis as a safety measure.
- To emphasize the need for individualized risk assessment and tailored prophylaxis strategies.
Main Methods:
- Review of randomized clinical trials and meta-analyses over 30 years.
- Analysis of evidence-based guidelines, including those published in Chest.
- Evaluation of data regarding bleeding complications associated with prophylaxis.
Main Results:
- Primary thromboprophylaxis demonstrably reduces DVT, pulmonary embolism (PE), and fatal PE.
- VTE prophylaxis is considered a highest safety practice for hospitalized patients.
- Clinical trial data indicate minimal to no increase in clinically significant bleeding rates with prophylaxis.
Conclusions:
- Thromboprophylaxis is essential for reducing VTE events following major orthopedic surgery.
- Surgeons must assess individual patient risk factors to optimize prophylaxis intensity.
- Current evidence supports the safety and efficacy of VTE prophylaxis in this patient population.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...